<DOC>
	<DOCNO>NCT00974584</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study ass safety , tolerability , pharmacokinetics oral ( PO ) GDC-0941 administer one three plan regimen : Arm A : paclitaxel carboplatin bevacizumab-ineligible NSCLC patient , Arm B : paclitaxel , carboplatin , bevacizumab bevacizumab-eligible NSCLC patient Arm C : pemetrexed , cisplatin , bevacizumab bevacizumab-eligible , non-squamous NSCLC patient .</brief_summary>
	<brief_title>A Study Safety Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin ( With Without Bevacizumab ) Pemetrexed , Cisplatin , And Bevacizumab Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically document NSCLC advance disease ( Stage IIIb eligible chemoradiotherapy Stage IV recurrent disease ) Adequate organ function assess laboratory test Evaluable disease disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST ) More one anticancer regimen ( chemotherapy radiotherapy ) advance NSCLC prior initiation study treatment Any adjuvant neoadjuvant anticancer therapy within specify timeframe prior first study treatment History Grade &gt; = 3 fast hyperglycemia diabetes require regular medication Active autoimmune disease , active infection require IV antibiotic , current uncontrolled illness History clinically significant cardiac pulmonary dysfunction History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease Any condition require fulldose anticoagulant , warfarin , heparin , thrombolytic agent Known brain metastasis untreated , symptomatic , require therapy Pregnancy , lactation , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PI3K</keyword>
	<keyword>Avastin</keyword>
</DOC>